|
[1]
|
本刊编辑部. 2017年中国最新癌症数据[J]. 中国肿瘤临床与康复, 2017, 24(6): 1.
|
|
[2]
|
Koo, C.Y., Muir, K.W. and Lam, W.F. (2012) FOXM1: From Cancer Initiation to Progression and Treatment. Biochimica et Biophysica Acta, 1819, 28-37. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Nandi, D., Cheema, P.S., Jaiswal, N. and Nag, A. (2018) Foxm1: Repurposing an Oncogene as a Biomarker. Seminars in Cancer Biology, 52, 74-84. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Gentles, A.J., Newman, A.M., Liu, C.L., et al. (2015) The Prognostic Landscape of Genes and Infiltrating Immune Cells across Human Cancers. Nature Medicine, 21, 938-945.
|
|
[5]
|
Okada, K. and Fujiwara, Y. (2013) Overexpression of Forkhead Box M1 Transcription Factor (FOXM1) Is a Potential Prognostic Marker and Enhances Chemoresistance for Docetaxel in Gastric Cancer. Annals of Surgical Oncology, 20, 1035-1043. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Jaiswal, N., Chakraborty, S. and Nag, A. (2014) Biology of FOXM1 and Its Emerging Role in Cancer Therapy. Journal of Proteins & Proteomics, 5, 1-24.
|
|
[7]
|
Xia, L., Huang, W., Tian, D., et al. (2012) Upregulated Foxm1 Expression Induced by Hepatitis B Virus X Protein Promotes Tumor Metastasis and Indicates Poor Prognosis in Hepatitis B Virus-Related Hepatocellular Carcinoma. Journal of Hepatology, 57, 600-612. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Chen, P.M. and Lee, H. (2015) FOXM1 Induced by E6 Oncoprotein Promotes Tumor Invasion and Chemoresistance in HPV-Infected Lung Cancer. Cancer Cell & Microenvironment, 2, 1-4.
|
|
[9]
|
Ye, H., Kelly, T.F., Samadani, U., et al. (1997) Hepatocyte Nuclear Factor 3/Fork Head Homolog 11 Is Expressed in Proliferating Epithelial and Mesenchymal Cells of Embryonic and Adult Tissues. Molecular and Cellular Biology, 17, 1626-1641. [Google Scholar] [CrossRef]
|
|
[10]
|
Egawa, M., Yoshida, Y., Ogura, S., et al. (2017) Increased Expression of Forkhead Box M1 Transcription Factor Is Associated with Clinicopathological Features and Confers a Poor Prognosis in Human Hepatocellular Carcinoma. Hepatology Research, 47, 1196-1205. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Calvisi, D.F., Pinna, F., Ladu, S., et al. (2009) Forkhead Box M1B Is a Determinant of Rat Susceptibility to Hepatocarcinogenesis and Sustains ERK Activity in Human HCC. Journal of Hepatology, 52, S345-S345. [Google Scholar] [CrossRef]
|
|
[12]
|
Tang, H.-M. (2011) Overexpression of Forkhead Box M1 Protein Associates with Aggressive Tumor Features and Poor Prognosis of Hepatocellular Carcinoma. Oncology Reports, 25, 1533-1539. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Shang, R., Pu, M., Li, Y., et al. (2017) FOXM1 Regulates Glycolysis in Hepatocellular Carcinoma by Transactivating Glucose Transporter 1 Expression. Oncology Reports, 37, 2261-2269. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Wei, J.C., Meng, F.D., Kai, Q.U., et al. (2015) Sorafenib Inhibits Proliferation and Invasion of Human Hepatocellular Carcinoma Cells via Up-Regulation of p53 and Suppressing Foxm1. Acta Pharmacologica Sinica, 36, 241-251. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Fei, C., Bai, G., Li, Y., et al. (2017) A Positive Feedback Loop of Long Noncoding RNA CCAT2 and FOXM1 Promotes Hepatocellular Carcinoma Growth. American Journal of Cancer Research, 7, 1423.
|
|
[16]
|
Hu, G., Yan, Z., Zhang, C., et al. (2019) FOXM1 Promotes Hepatocellular Carcinoma Progression by Regulating KIF4A Expression. Journal of Experimental & Clinical Cancer Research, 38, 188. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Saha, S.K., Zhu, A.X., Fuchs, C.S. and Brooks, G.A. (2016) Forty-Year Trends in Cholangiocarcinoma Incidence in the US: Intrahepatic Disease on the Rise. Oncologist, 21, 594-599. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Levy, C., et al. (2005) The Value of Serum CA 19-19 in Predicting Cholangiocarcinomas in Patients with Primary Sclerosing Cholangitis. Digestive Diseases and Sciences, 50, 1734-1740. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Jiao, X., Yu, W., Qian, J., et al. (2018) ADAM-17 Is a Poor Prognostic Indicator for Patients with Hilar Cholangiocarcinoma and Is Regulated by Foxm1. BMC Cancer, 18, 570. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Wang, L., Liu, Y. and Yu, G. (2019) Avasimibe Inhibits Tumor Growth by Targeting Foxm1-AKR1C1 in Osteosarcoma. OncoTargets and Therapy, 12, 815-823. [Google Scholar] [CrossRef]
|
|
[21]
|
Gao, Y., Xu, D., Li, H., et al. (2021) Avasimibe Dampens Cholangiocarcinoma Progression by Inhibiting Foxm1-AKR1C1 Signaling. Frontiers in Oncology, 11, Article ID: 677678. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Intuyod, K., Saavedra-García, P., Zona, S., et al. (2018) FOXM1 Modulates 5-Fluorouracil Sensitivity in Cholangiocarcinoma through Thymidylate Synthase (TYMS): Implications of FOXM1-TYMS Axis Uncoupling in 5-FU Resistance. Cell Death & Disease, 9, 1185. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Dixon, E., Vollmer, C.M.J., Sahajpal, A., et al. (2005) An Aggressive Surgical Approach Leads to Improved Survival in Patients with Gallbladder Cancer: A 12-Year Study at a North American Center. Annals of Surgery, 241, 385-394. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Wang, R.T., Miao, R.C., Zhang, X., et al. (2021) Fork Head Box M1 Regulates Vascular Endothelial Growth Factor—A Expression to Promote the Angiogenesis and Tumor Cell Growth of Gallbladder Cancer. World Journal of Gastroenterology, 27, 692-707. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Tao, J., Xu, X.S., Song, Y.Z., et al. (2014) Down-Regulation of Foxm1 Inhibits Viability and Invasion of Gallbladder Carcinoma Cells, Partially Dependent on Inducement of Cellular Senescence. World Journal of Gastroenterology, 20, 9497-9505.
|
|
[26]
|
Wang, S.H., Ma, F., Tang, Z.H., et al. (2016) Long Non-Coding RNA H19 Regulates FOXM1 Expression by Competitively Binding Endogenous miR-342-3p in Gallbladder Cancer. Journal of Experimental & Clinical Cancer Research, 35, 160. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Cui, J., Shi, M., Xie, D., et al. (2014) FOXM1 Promotes the Warburg Effect and Pancreatic Cancer Progression via Transactivation of LDHA Expression. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 20, 2595-2606. [Google Scholar] [CrossRef]
|
|
[28]
|
Mao, L.X., et al. (2018) CSN5 Promotes the Invasion and Metastasis of Pancreatic Cancer by Stabilization of FOXM1. Experimental Cell Research, 374, 274-281.
|
|
[29]
|
Liu, C., Shi, J., Li, Q., et al. (2019) STAT1-Mediated Inhibition of FOXM1 Enhances Gemcitabine Sensitivity in Pancreatic Cancer. Clinical Science, 133, 645-663. [Google Scholar] [CrossRef]
|
|
[30]
|
Song, Z., Li, J., Zhang, L., et al. (2019) UCHL3 Promotes Pancreatic Cancer Progression and Chemo-Resistance through FOXM1 Stabilization. American Journal of Cancer Research, 9, 1970-1981.
|
|
[31]
|
Quan, M., Cui, J., Xia, T., et al. (2015) Merlin/NF2 Suppresses Pancreatic Tumor Growth and Metastasis by Attenuating the FOXM1-Mediated Wnt/β-Catenin Signaling. Cancer Research, 75, 4778-4789. [Google Scholar] [CrossRef]
|
|
[32]
|
Liu, W., Tang, J., Zhang, H., et al. (2020) A Novel lncRNA PTTG3P/miR-132/212-3p/Foxm1 Feedback Loop Facilitates Tumorigenesis and Metastasis of Pancreatic Cancer. Cell Death Discovery, 6, Article No. 136.
|